Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide
Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…Improvement of movement disorder and neurodevelopment under selegiline in a CLTC deficient patient
Objective: We report the significative improvement on both movement disorder and neurodevelopment in a 5-year-old CLTC deficient patient treated with selegiline. Background: In 2019 we described a 30-year-old woman…SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.
Objective: Evaluate the efficacy of safinamide in fluctuations in Parkinson's disease in real life. Analysis by subgroups: Switch rasagiline to safinamide and treatment with low…Safinamide adherence: the experience of the movement disorder unit of Trieste.
Objective: Describe the clinical experience with Safinamide and assess the patients’ adherence to this treatment in the movement disorders centre of Trieste-Italy. Background: Safinamide (Xadago®)…Effects of safinamide adjunct therapy on non-motor symptoms in patients with Parkinson’s disease: a post-hoc analysis of the Japanese Phase 2/3 study
Objective: To evaluate the efficacy of safinamide for mood and pain by a post-hoc analysis of the Japanese phase 2/3 double-blind study (JapicCTI-153056) in patients…Safinamide Improves Sleep and Daytime Sleepiness in Parkinson´s Disease. Results from the SAFINONMOTOR Study
Objective: Our aim was to analyze the effectiveness of safinamide on sleep in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.
Objective: Our aim was to analyze the effectiveness of safinamide on mood in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…Improved Excessive Daytime Sleepiness with Selegiline in patients with Parkinson’s Disease: An Open Trial
Objective: This study, an open-labeled trial, was aimed to assess the efficacy and safety of selegiline on the treatment of EDS in PD patients. Background: Excessive Daytime…Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease
Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »